Yunnan Baiyao Group Co.,Ltd

000538

CNE0000008X7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
55.46 ^CNY	-0.82%		+4.03%	+12.84%

Apr. 01	Yunnan Baiyao Group Co.,Ltd Proposes Final Cash Dividend for 2023	CI
Apr. 01	Yunnan Baiyao Group's Profit Rises 30% as Operating Income Increases	MT

Yunnan Baiyao Group Co.,Ltd authorizes a Buyback Plan.

April 07, 2022

The Board of Directors of Yunnan Baiyao Group Co.,Ltd has authorized a buyback plan on April 8, 2022.

Latest news about Yunnan Baiyao Group Co.,Ltd

Yunnan Baiyao Group Co.,Ltd Proposes Final Cash Dividend for 2023	Apr. 01	CI
Yunnan Baiyao Group's Profit Rises 30% as Operating Income Increases	Apr. 01	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Shanghai Pharma, Yunnan Baiyao Renew Sales, Procurement Deal	Dec. 22	MT
Yunnan Baiyao’s Profit Jumps 61% in Q3 as Revenue Rises 5%	23-10-31	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
YNBY International Plans Year-End Date Change	23-10-16	MT
Yunnan Baiyao’s Profit Jumps 88.5% in H1 as Revenue Rises 13%	23-08-30	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Yunnan Baiyao Group Co.,Ltd. Approves Cash Dividend for the Year 2022, Payable on 19 May 2023	23-05-10	CI
Chinese Shares Rebound; Yunnan Baiyao Jumps 7.5% on Robust Q1 Earnings	23-04-27	MT
Yunnan Baiyao’s Q1 Profit Jumps 66% as Revenue Rises 11.5%; Shares Climb 7%	23-04-27	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Yunnan Baiyao Group Co.,Ltd's Equity Buyback announced on May 9, 2022, has expired.	23-04-06	CI
Yunnan Baiyao Group Co.,Ltd Proposes Final Cash Dividend for 2022	23-03-31	CI
Yunnan Baiyao Chairman Steps Down; Shares Fall 4%	23-03-07	MT
Yunnan Baiyao Group Co.,Ltd agreed to acquire Product Registration and Promotion, Global Supply and Professional Supporting Services of Ban Loong from Ban Loong Holdings Limited (SEHK:30).	22-12-22	CI
Yunnan Baiyao Group Co.,Ltd Announces Directorate Appointments	22-11-08	CI
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Yunnan Baiyao to Use Huawei’s AI Tech in Developing Drugs	22-07-25	MT
Yunnan Baiyao Group Co.,Ltd announces a Decrease in Equity Buyback.	22-06-01	CI
Yunnan Baiyao Group Co.,Ltd commences an Equity Buyback Plan for CNY 1,119.42 million worth of its shares, under the authorization approved on April 20, 2022.	22-05-09	CI
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Yunnan Baiyao Group Co.,Ltd Approves Final Cash Dividend for 2021	22-04-21	CI

Chart Yunnan Baiyao Group Co.,Ltd

Duration

Period

More charts

Yunnan Baiyao Group Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical products. The group proposes primarily traditional medicine products, phytobiological products, body care products, antibiotics and anti-inflammatory. China accounts for 98.9% of net sales.

Sector

Pharmaceuticals

Calendar

2024-04-26 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Yunnan Baiyao Group Co.,Ltd

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

55.46 CNY

Average target price

62.1 CNY

Spread / Average Target

+11.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
YUNNAN BAIYAO GROUP CO.,LTD	+12.84%	13.77B
ELI LILLY AND COMPANY	+25.89%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.16%	360B
MERCK & CO., INC.	+16.76%	321B
ABBVIE INC.	+8.40%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.65%	149B

Other Pharmaceuticals